Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TGN-1412 monoclonal antibody

Known as: TGN 1412, monoclonal antibody TGN1412, TAB08 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08
CD28 superagonists (CD28SAs) are potent T‐cell‐activating monoclonal antibodies (mAbs). In contrast to their benign behavior and… Expand
Highly Cited
2013
Highly Cited
2013
After TGN1412: Recent developments in cytokine release assays
The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically… Expand
Highly Cited
2011
Highly Cited
2011
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
Human volunteers receiving TGN1412, a humanized CD28-specific monoclonal antibody, experienced a life-threatening cytokine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cells
BACKGROUND AND PURPOSE In 2006, a life‐threatening ‘cytokine storm’, not predicted by pre‐clinical safety testing, rapidly… Expand
Highly Cited
2010
Highly Cited
2010
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
TGN1412 is a "superagonistic" CD28 monoclonal antibody (IgG4) that caused serious adverse events at its first time in human… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
 
Highly Cited
2007
Highly Cited
2007
“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics
The CD28-specific mAb TGN1412 rapidly caused a life-threatening “cytokine storm” in all six healthy volunteers in the Phase I… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2006
Highly Cited
2006
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2006
Highly Cited
2006
Learning from the TGN1412 trial
  • M. Goodyear
  • BMJ : British Medical Journal
  • 2006
    • Corpus ID: 32298471
This experience should foster an open culture in medical research 
2006
2006
Violent Reaction to Monoclonal Antibody Therapy Remains a Mystery
CAMBRIDGE, U.K.-- On 13 March, six healthy volunteers in a clinical trial were injected with a "superagonist," a drug meant to… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE